SG&A Efficiency Analysis: Comparing TG Therapeutics, Inc. and Rhythm Pharmaceuticals, Inc.

Biotech SG&A: A Decade of Strategic Spending

__timestampRhythm Pharmaceuticals, Inc.TG Therapeutics, Inc.
Wednesday, January 1, 2014121300024518692
Thursday, January 1, 2015342500019886580
Friday, January 1, 2016631100012631689
Sunday, January 1, 2017951800021977998
Monday, January 1, 20182808000020759000
Tuesday, January 1, 20193655000020838000
Wednesday, January 1, 202046125000121812000
Friday, January 1, 202168486000152137000
Saturday, January 1, 20229203200083231000
Sunday, January 1, 2023117532000122706000
Loading chart...

Unlocking the unknown

SG&A Efficiency: A Tale of Two Biotechs

In the competitive world of biotechnology, managing operational costs is crucial for success. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of TG Therapeutics, Inc. and Rhythm Pharmaceuticals, Inc. over the past decade. From 2014 to 2023, TG Therapeutics saw a significant increase in SG&A expenses, peaking in 2021 with a 540% rise from 2014. Meanwhile, Rhythm Pharmaceuticals experienced a staggering 9,600% increase in the same period, highlighting its aggressive expansion strategy.

Key Insights

  • 2014-2017: Both companies maintained relatively stable expenses, with TG Therapeutics consistently outspending Rhythm Pharmaceuticals.
  • 2018-2023: A shift occurred as Rhythm Pharmaceuticals' expenses surged, surpassing TG Therapeutics by 2023.
    This trend underscores the dynamic nature of biotech financial strategies, where efficient SG&A management can be a key differentiator in achieving long-term growth.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025